| ReMIND – Discovery Stage ReMIND | Aparna Bhaduri PhD | Defining Neurovascular Metabolism in Neurodevelopmental and Neuropsychiatric Disorders |
$10,330,000 |
| Shared Labs Grant – Enhancing/Expanding SRLs | Dr. Kathrin Plath Dr. | A modular automation approach to stem cell modeling to increase throughput, reproducibility and access |
$3,999,999 |
| Manufacturing Network Grant | Dr. Dawn Ward | Enhancing California’s Manufacturing of Leading-Edge Cell & Gene Therapies |
$2,000,000 |
| Foundation – Discovery Stage Research Projects | Dr. M. Carrie Miceli | Interrogating Satellite Cell and Myofiber Defects and Repair in Human DMD using Single Nuclei/Single Cell RNA Sequencing of Muscle Resident Cells |
$1,578,000 |
| Foundation – Discovery Stage Research Projects | Michael F Wells | Village-based identification of human risk factors for viral neuropathogenesis |
$1,577,448 |
| Foundation – Discovery Stage Research Projects | Dr. William Lowry Dr. | Defining the source of dysfunction in monogenic Intellectual Disability Syndrome neurons |
$1,500,337 |
| Foundation – Discovery Stage Research Projects | Dr. Kathrin Plath Dr. | Characterization and applications of human blastoids for understanding early human embryogenesis |
$1,402,137 |
| Foundation – Discovery Stage Research Projects | Dr. Brigitte N Gomperts | Overcoming barriers for airway stem cell gene therapy for Cystic Fibrosis |
$1,472,858 |
| Foundation – Discovery Stage Research Projects | UCLA Gay M Crooks | Engineering pluripotent stem cells for universally available, off-the-shelf T cell therapies |
$1,352,753 |
| Foundation – Discovery Stage Research Projects | Dr Melissa Jan Spencer | Engineering AAV capsids for transduction of neural and muscle stem cells |
$999,999 |
| Therapeutic Translational Research Projects | Dr. Vaithilingaraja Arumugaswami PhD | COVID-19 Antiviral Therapy to Block Direct Cell Injury and Associated Tissue Damage |
$349,999 |
| Discovery Research Projects | Dr. Lili Yang | Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells |
$250,000 |
| Discovery Research Projects | Prof. Song Li | Biomaterial vaccine to enhance the formation of SARS-CoV-2-specific T memory stem cells |
$149,916 |
| Discovery Research Projects | UCLA Gay M Crooks | Stem cell-based rapid identification of SARS-CoV-2 T cell epitopes and T cell receptors for therapeutic use |
$126,692 |
| Discovery Research Projects | Dr. Brigitte N Gomperts | Identifying a lead compound for COVID19 using high throughput screening with lung stem cell organoids |
$149,998 |
| Conference – The 2018 Alpha Stem Cell Clinic Annual Symposium | John S. Adams | Delivery of Stem Cell Therapeutics to Patients |
$60,000 |
| Alpha Stem Cell Clinics Network Expansion | Dr. Noah Carvajal Federman | Expansion of the Alpha Stem Cell and Gene Therapy Clinic at UCLA |
$8,000,000 |
| Conference – Lung Regenerative Medicine Workshop | Dr. Brigitte N Gomperts | Stem Cells for Lung Diseases – Overcoming Barriers to Find New Therapies |
$44,548 |
| Quest – Discovery Stage Research Projects | Dr. Koki Morizono | B cell receptor-mediated lentiviral expression of anti-HIV antibody |
$2,751,504 |
| Quest – Discovery Stage Research Projects | Prof. Song Li | Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
| Quest – Discovery Stage Research Projects | Dr. Richard Joseph Pietras | Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
| Quest – Discovery Stage Research Projects | Dr. Gerald Lipshutz | Gene Therapy for SLC6A8 Creatine Transporter Disorder |
$2,296,920 |
| Quest – Discovery Stage Research Projects | Frank Pajonk | Development of novel small molecules against cancer stem cells in solid cancers |
$2,340,000 |
| Quest – Discovery Stage Research Projects | Dr. Lili Yang | Combating Ovarian Cancer Using Stem Cell-Engineered Off-The-Shelf CAR-iNKT Cells |
$1,402,662 |
| Quest – Discovery Stage Research Projects | Dr. Xian-Jie Yang | Developing gene therapy for dominant optic atrophy using human pluripotent stem cell-derived retinal organoid disease models |
$1,345,691 |
| Quest – Discovery Stage Research Projects | Dr Dinesh S Rao | Novel methods to eliminate cancer stem cells |
$1,384,345 |
| Quest – Discovery Stage Research Projects | Dr. Caroline Y. Kuo | Defining the Optimal Gene Therapy Approach of Human Hematopoietic Stem Cells for the Treatment of Dedicator of Cytokinesis 8 (DOCK8) Deficiency |
$1,386,232 |
| Quest – Discovery Stage Research Projects | Dr. Donald B. Kohn | Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$1,177,739 |
| Quest – Discovery Stage Research Projects | Prof. Song Li | iPSC Extracellular Vesicles for Diabetes Therapy |
$1,354,928 |
| Quest – Discovery Stage Research Projects | Dr. Thomas Carmichael M.D., Ph.D. | Human-induced pluripotent stem cell-derived glial enriched progenitors to treat white matter stroke and vascular dementia. |
$250,000 |
| Quest – Discovery Stage Research Projects | Dr. Donald B. Kohn | Hematopoietic Stem Cell Gene Therapy for X-linked Agammaglobulinemia |
$219,230 |
| Quest – Discovery Stage Research Projects | Dr. Lili Yang | Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
| Quest – Discovery Stage Research Projects | Dr. Scott G Kitchen | Engineering Lifelong Cellular Immunity to HIV |
$1,701,178 |
| Quest – Discovery Stage Research Projects | Dr. Thomas Carmichael M.D., Ph.D. | iPS Glial Therapy for White Matter Stroke and Vascular Dementia |
$2,086,130 |
| Quest – Discovery Stage Research Projects | Dr. April Pyle Ph.D. | Identification and Generation of Long Term Repopulating Human Muscle Stem Cells from Human Pluripotent Stem Cells |
$2,148,519 |
| Quest – Discovery Stage Research Projects | Dr. Vaithilingaraja Arumugaswami PhD | Immunization strategies to prevent Zika viral congenital eye and brain disease |
$2,128,867 |
| Quest – Discovery Stage Research Projects | UCLA Gay M Crooks | Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
| Quest – Discovery Stage Research Projects | Dr. Caroline Y. Kuo | Targeted Gene Editing in the Treatment of X-Linked Hyper-IgM Syndrome |
$1,512,333 |
| Quest – Discovery Stage Research Projects | Dr. John P Chute | Protein tyrosine phosphatase – sigma inhibitors for hematopoietic regeneration |
$2,115,735 |
| Quest – Discovery Stage Research Projects | Dr. April Pyle Ph.D. | CRISPR/Cas9 nanoparticle enabled therapy for Duchenne Muscular Dystrophy in muscle stem cells |
$2,150,400 |
| Inception – Discovery Stage Research Projects | Alireza Moshaverinia | Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration |
$194,483 |
| Inception – Discovery Stage Research Projects | Dr. Owen N Witte M.D. | Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
| Inception – Discovery Stage Research Projects | Dr. April Pyle Ph.D. | Novel Platforms to Enhance In Vivo Delivery of Skeletal Muscle Progenitor Cells from Human Pluripotent Stem Cells |
$230,400 |
| Inception – Discovery Stage Research Projects | Dr. Bennett G Novitch Ph.D. | Organoid Modeling of Human Cortical Microcircuits |
$208,916 |
| Inception – Discovery Stage Research Projects | Dr. Arjun Deb | Targeting progenitors in scar tissue to reduce chronic scar burden |
$230,400 |
| Inception – Discovery Stage Research Projects | Dr. Thomas Carmichael M.D., Ph.D. | iPS-Interneuron Transplantation for Neural Repair after Stroke |
$229,396 |
| Therapeutic Translational Research Projects | Roger Hollis | Evaluation of an ex vivo lentiviral gene therapy for the treatment of Angelman syndrome |
$5,276,765 |
| Therapeutic Translational Research Projects | Dr. Donald B. Kohn | Hematopoietic Stem Cell Gene Therapy for Alpha Thalassemia |
$5,028,351 |
| Therapeutic Translational Research Projects | Dr. Lili Yang | Combating Ovarian Cancer with Stem Cell-Engineered Off-The-Shelf CAR-NKT Cell Therapy |
$5,601,600 |
| Therapeutic Translational Research Projects | Dr. Gerald Lipshutz | Development of a Gene Therapy for Treatment of Guanidinoacetate Methyltransferase Deficiency-Translating In Vivo Proof of Concept to Support a Pre-IND |
$5,145,825 |
| Therapeutic Translational Research Projects | Zulema Romero Garcia | Adenine Base Editing for Autologous Hematopoietic Stem Cell Gene Therapy of CD3δ SCID |
$5,966,928 |
| Therapeutic Translational Research Projects | Dr. Caroline Y. Kuo | Hematopoietic Stem Cell Gene Editing for X-linked Agammaglobulinemia (XLA) |
$4,304,883 |
| Therapeutic Translational Research Projects | Dr. Gerald Lipshutz | Development of a Gene Therapy for the Treatment of Arginase Deficiency – Translating from Proof of Concept to Support Pre-IND Meeting |
$5,266,504 |
| Therapeutic Translational Research Projects | Anthony J Aldave | AAV Gene Therapy for Treating Congenital Hereditary Endothelial Dystrophy associated with Biallelic SLC4A11 Mutations |
$4,338,166 |
| Therapeutic Translational Research Projects | Dr. Sophie X Deng | Extracellular Vesicle-Based Therapy for Corneal Scars |
$5,779,276 |
| Therapeutic Translational Research Projects | Dr. Scott G Kitchen | Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection |
$6,140,723 |
| Therapeutic Translational Research Projects | Dr. Donald B. Kohn | Autologous MPO Knock-Out Hematopoietic Stem and Progenitor Cells for Pulmonary Arterial Hypertension |
$4,751,297 |
| Therapeutic Translational Research Projects | Dr. Arjun Deb | Targeting stromal progenitors to prevent the development of heart failure |
$4,714,824 |
| Therapeutic Translational Research Projects | Dr. Irene L. Llorente | Clinical Translation of Allogenic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia |
$707,754 |
| Therapeutic Translational Research Projects | Cristina Puig Saus | CAR-Tnm cell therapy for melanoma targeting TYRP-1 |
$5,904,462 |
| Therapeutic Translational Research Projects | Dr. Lili Yang | HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma |
$5,281,199 |
| Therapeutic Translational Research Projects | Yvonne Y. Chen | BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
| Therapeutic Translational Research Projects | Dr. Caroline Y. Kuo | Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome |
$4,896,628 |
| Therapeutic Translational Research Projects | Steven Schwartz | Clinical Translation of Autologous Regenerative Cell Therapy for Blindness |
$5,068,026 |
| Therapeutic Translational Research Projects | Dr. Peter Cawood Butler | Personalized Cell Therapy for Diabetes |
$1,494,896 |
| Therapeutic Translational Research Projects | Dr. Lili Yang | Stem Cell-Based iNKT Cell Therapy for Cancer |
$6,956,775 |
| Conference II | Mark Wisniewski | Los Angeles Bioscience Ecosystem Summit Twenty 24 (LABEST 24) |
$50,000 |
| Conference II | Song Li | The 18th Annual UC System-Wide Bioengineering Symposium |
$25,000 |
| Conference II | Dr. Donald B. Kohn | Primary Immune Deficiency Treatment Consortium (PIDTC) Annual Scientific Workshop |
$29,807 |
| Clinical Trial Stage Projects | Dr. Donald B. Kohn | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS-ADA lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$14,325,181 |
| Clinical Trial Stage Projects | Dr. Jeffrey L Veale | The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program |
$6,717,608 |
| Clinical Trial Stage Projects | Dr. Sophie X Deng | Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
| Clinical Trial Stage Projects | Theodore Scott Nowicki | Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,230,000 |
| Clinical Trial Stage Projects | Dr. Steven M. Dubinett M.D. | A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$9,586,937 |
| Clinical Trial Stage Projects | Dr. Donald B. Kohn | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Clinical Trial Stage Projects | Dr. Donald B. Kohn | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
| Clinical Trial Stage Projects | Dr. Donald B. Kohn | A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
| Late Stage Preclinical Projects | Dr. Arjun Deb | Development of a therapeutic monoclonal antibody for the treatment of myocardial infarction and heart failure |
$5,999,998 |
| Late Stage Preclinical Projects | Dr. Jerome A. Zack Ph.D. | Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness |
$6,000,000 |
| Late Stage Preclinical Projects | Dr. Antoni Ribas MD/PhD | Skin regeneration and wound healing with a topical BRAF inhibitor |
$5,005,126 |
| Late Stage Preclinical Projects | Dr. Sophie X Deng | Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy |
$4,244,211 |
| Alpha Stem Cell Clinics | John S. Adams | UCLA-UCI Alpha Stem Cell Clinic (ASCC) Consortium |
$8,680,000 |
| Tools and Technologies III | Dr. James C. Dunn Dr. | Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$1,044,423 |
| Tools and Technologies III | Dr. Hanna Mikkola | A suite of engineered human pluripotent stem cell lines to facilitate the generation of hematopoietic stem cells |
$1,382,400 |
| Tools and Technologies III | Dr. Carla M. Koehler | A small molecule tool for reducing the malignant potential in reprogramming human iPSCs and ESCs |
$1,283,900 |
| Tools and Technologies III | Leif Havton | Development of a Relevant Pre-Clinical Animal Model as a Tool to Evaluate Human Stem Cell-Derived Replacement Therapies for Motor Neuron Injuries and Degenerative Diseases |
$1,308,711 |
| Conference | Dr. Martina Wiedau-Pazos | California ALS Summit 2011 |
$13,300 |
| Conference | Dr. Tatiana Segura | 2013 Materials Research Society (MRS) Spring Meeting Symposium
“Design of Cell Instructive Materials” |
$4,000 |
| Conference | Dr. Irvin SY Chen | Stem Cells: A New Avenue of HIV Research and New Approaches to HIV Treatment |
$24,456 |
| Conference | Dr. Dana Leanne Jones | 7th CA/HSCI Junior PI Conference: Stem Cells 2.0 |
$2,500 |
| Disease Team Planning | Dr. Irvin SY Chen | Stem Cell Therapy for AIDS- Disease Team Planning |
$51,490 |
| Disease Team Planning | Dr. Stanley Thomas Carmichael | Development of a Stem Cell Therapy to Promote Functional Recovery in Stroke |
$42,748 |
| Major Facilities | Dr. Gene D. Block | UCLA CIRM Institute |
$19,854,900 |
| Basic Biology V | Dr. Bennett G Novitch | In vitro modeling of human motor neuron disease |
$1,148,758 |
| Basic Biology V | Dr Samantha J Butler Ph.D. | Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate |
$515,730 |
| Basic Biology V | Dr. Denis A Evseenko Dr. | Promoting survival and countering hypertrophy of pluripotent stem cell (PSC)-derived chondrocytes |
$411,330 |
| Basic Biology V | Dr. Lili Yang | Differentiation of Human Hematopoietic Stem Cells into iNKT Cells |
$614,400 |
| Disease Team Therapy Development III | Dr. Dennis J Slamon | A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors |
$5,683,693 |
| Disease Team Therapy Development III | Dr. Donald B. Kohn | Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease |
$10,351,535 |
| Patent Assistance Fund Awards | Adele Rennie | Patent Assistance Fund – UCLA |
$84,973 |
| Early Translational from Disease Team Conversion | Dr. Irvin SY Chen | Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. |
$1,505,000 |
| Early Translational from Disease Team Conversion | Dr. Stanley Nelson | Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$1,823,545 |
| Early Translational IV | Dr. Robert Reiter MD | Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
| Early Translational IV | Dr. Jerome A. Zack Ph.D. | Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection |
$4,925,166 |
| Early Translational IV | Dr. Gerald Lipshutz | Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders |
$1,801,629 |
| Early Translational IV | Dr. Donald B. Kohn | Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells |
$1,651,884 |
| Tissue Collection for Disease Modeling | Dr. Brigitte N Gomperts | Using human induced pluripotent stem cells to improve our understanding of Idiopathic Pulmonary Fibrosis |
$811,231 |
| New Faculty Physician Scientist | Dr. Ali Nsair MD | Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. |
$2,316,894 |
| New Faculty Physician Scientist | Dr. Reza Ardehali MD, PhD | Preclinical evaluation of human embryonic stem cell-derived cardiovascular progenitors in a large animal model |
$2,930,388 |
| Basic Biology IV | Dr. Owen N Witte M.D. | Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells |
$1,254,960 |
| Basic Biology IV | Dr. Kathrin Plath Dr. | Understanding the status of the X chromosomes in human ESCs and preimplantation embryos |
$1,382,400 |
| Disease Team Therapy Development – Research | Dr. Antoni Ribas MD/PhD | Genetic Re-programming of Stem Cells to Fight Cancer |
$14,144,221 |
| Disease Team Therapy Development – Research | Dr. Stanley Nelson | Combination Therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$0 |
| Training Grant I-1 | Dr. Owen N Witte M.D. | CIRM Type I Comprehensive Training Program |
$3,660,398 |
| Disease Team Therapy Planning I | Dr. Stanley Nelson | Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$68,947 |
| Disease Team Therapy Planning I | Dr. Antoni Ribas MD/PhD | Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
| Research Training II | Kenneth Dorshkind | UCLA CIRM Research Training Program II |
$7,790,488 |
| Basic Biology III | Dr. Yi Eve Sun | Studying neurotransmission of normal and diseased human ES cell-derived neurons in vivo |
$1,382,400 |
| Basic Biology III | Dr. Kathrin Plath Dr. | Discovery of mechanisms that control epigenetic states in human reprogramming and pluripotent cells |
$1,364,598 |
| Basic Biology III | Dr. Ali Nsair MD | Characterization and Engineering of the Cardiac Stem Cell Niche |
$1,127,741 |
| Basic Biology III | Dr. William Lowry Dr. | Molecular determinants of accurate differentiation from human pluripotent stem cells |
$677,115 |
| Basic Biology III | Dr. Shuo Lin Dr. | Etsrp/ER71 mediated stem cell differentiation into vascular lineage |
$1,378,781 |
| Basic Biology III | UCLA Gay M Crooks | Forming the Hematopoietic Niche from Human Pluripotent Stem Cells |
$1,252,857 |
| Tools and Technologies II | Dr. Richard A. Gatti | Use of hiPSCs to develop lead compounds for the treatment of genetic diseases |
$1,833,054 |
| Tools and Technologies II | Dr. Thomas Carmichael M.D., Ph.D. | Development of a Hydrogel Matrix for Stem Cell Growth and Neural Repair after Stroke |
$1,825,613 |
| Tools and Technologies II | Dr. Martin Gabriel Martin | Pluripotent and Somatic Stem Cell Models to Study Inherited Diarrheal Disorders |
$1,783,250 |
| Early Translational II | Dr. Sophie X Deng | Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$697,507 |
| Early Translational II | Dr. Sophie X Deng | Regeneration of Functional Human Corneal Epithelial Progenitor Cells |
$1,524,947 |
| Early Translational II | Leif Havton | Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons |
$75,628 |
| Early Translational II | Dr. Noriyuki Kasahara | Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
| Early Translational II | Prof. Bruno Peault | Harnessing native fat-residing stem cells for bone regeneration |
$5,359,076 |
| Research Leadership | Dr. John P Chute | Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
| New Faculty I | Dr. Dana Leanne Jones | Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$382,773 |
| New Faculty I | Dr. Siavash Kurdistani | Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
| New Faculty I | Dr. Kathrin Plath Dr. | In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
| New Faculty I | Dr. Hanna Mikkola | Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
| Early Translational I | Dr. Gabriel H. Travis | Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Transplantation Immunology | UCLA Gay M Crooks | Engineering Thymic Regeneration to Induce Tolerance |
$1,235,445 |
| Tools and Technologies I | Dr. Michael E. Phelps | Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies |
$914,039 |
| Tools and Technologies I | Dr. Hsian-Rong Tseng | Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells |
$914,096 |
| Shared Labs | Scott Waugh | CIRM Shared Research Laboratories |
$2,000,000 |
| Shared Labs | Dr. Owen N Witte M.D. | CIRM Shared Research Laboratories |
$1,751,297 |
| New Faculty II | Dr. Antoni Ribas MD/PhD | Stem Cells for Immune System Regeneration to Fight Cancer |
$3,072,000 |
| New Faculty II | Dr. Brigitte N Gomperts | Stem Cells in Lung Cancer |
$2,381,572 |
| New Cell Lines | Dr. Jerome A. Zack Ph.D. | Generation of clinical grade human iPS cells |
$1,341,000 |
| New Cell Lines | Dr. Amander Clark Dr. | Generation of Pluripotent Cell Lines from Human Embryos |
$1,167,416 |
| Comprehensive Grant | Dr. Jerome A. Zack Ph.D. | Human Embryonic Stem Cell Therapeutic Strategies to Target HIV Disease |
$2,401,903 |
| Comprehensive Grant | UCLA Gay M Crooks | Regulated Expansion of Lympho-hematopoietic Stem and Progenitor Cells from Human Embryonic Stem Cells (hESC) |
$1,653,416 |
| Comprehensive Grant | Dr. Guoping Fan Dr. | Epigenetic gene regulation during the differentiation of human embryonic stem cells: Impact on neural repair |
$2,412,995 |
| SEED Grant | Dr. Noriyuki Kasahara | Down-Regulation of Alloreactive Immune Responses to hES Cell-Derived Graft Tissues |
$399,239 |
| SEED Grant | Dr. Hanna Mikkola | Improving microenvironments to promote hematopoietic stem cell development from human embryonic stem cells |
$550,241 |
| SEED Grant | Dr. William Lowry Dr. | Modeling Human Embryonic Development with Human Embryonic Stem Cells |
$528,096 |
| SEED Grant | Dr. Siavash Kurdistani | Cellular epigenetic diversity as a blueprint for defining the identity and functional potential of human embryonic stem cells |
$549,698 |
| SEED Grant | Dr. Zoran Galic | Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells |
$616,800 |
| SEED Grant | Dr. Irvin SY Chen | Genetic modification of the human genome to resist HIV-1 infection and/or disease progression |
$616,800 |
| SEED Grant | Dr. Michael A. Teitell | Role of Mitochondria in Self-Renewal Versus Differentiation of Human Embryonic Stem Cells |
$543,274 |
| Basic Biology II | Dr. Douglas L. Black | Programs of alternative splicing regulation by polypyrimidine tract binding protein |
$1,344,562 |
| Basic Biology II | Dr. Benhur Lee | The EphrinB2/EphB4 axis in regulating hESC pluripotency and differentiation |
$1,371,936 |
| Basic Biology II | Dr. Yong Kim | Novel Mechanism in Self-Renewal/Differentiation of Human Embryonic Stem Cells |
$1,259,371 |
| Disease Team Research I | Dr. Donald B. Kohn | Stem Cell Gene Therapy for Sickle Cell Disease |
$8,833,695 |
| Disease Team Research I | Dr. Irvin SY Chen | HPSC based therapy for HIV disease using RNAi to CCR5. |
$9,905,604 |
| Disease Team Research I | Dr. Dennis J Slamon | Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
| Basic Biology I | Dr. Michael A. Teitell | Mitochondrial Metabolism in hESC and hiPSC Differentiation, Reprogramming, and Cancer |
$1,323,029 |
| Basic Biology I | Dr. Bennett G Novitch Ph.D. | Molecular Characterization of hESC and hIPSC-Derived Spinal Motor Neurons |
$1,228,278 |
| Basic Biology I | Dr. Robb Maclellan Dr. | Human Cardiovascular Progenitors, their Niches and Control of Self-renewal and Cell Fate |
$917,667 |
| Basic Biology I | Dr. Luisa Iruela-Arispe | Molecular Characterization and Functional Exploration of Hemogenic Endothelium |
$1,371,477 |
| COMPASS Training Grant | Tracy L Johnson | COMPASS: Accelerating Stem Cell Research by Educating and Empowering New Stem Cell Researchers |
$2,910,000 |
| Research Training Grant | William Lowry | UCLA Training Program in Stem Cell Biology |
$5,373,742 |
| Progression Award – Discovery Stage Research Projects | Dr. Caroline Y. Kuo | Evaluation of Gene Therapy Approaches for Autosomal Recessive Hyper IgE Syndrome Due to Mutations in DOCK8 |
$234,000 |
